BJHEALTH：SUPPLEMENTALANNOUNCEMENTINRELATIONTOTHEANNUALREPORTFORTHEYEARENDED31DECEMBER2024.pdf

1、 1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in rel

2、iance upon the whole or any part of the contents of this announcement.(Incorporated in the Cayman Islands with limited liability)(Stock Code:2389)SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024Reference is made to the annual report of Beijing Health(Hol

3、dings)Limited(the“Company”)for the year ended 31 December 2024 published on 22 April 2025(the“2024 Annual Report”).Unless otherwise defined,capitalised terms used herein shall have the same meanings as those defined in the 2024 Annual Report.This announcement provides supplemental information to the

4、 2024 Annual Report and should be read in conjunction with the 2024 Annual Report.SHARE OPTION SCHEMEIn addition to the information provided in the 2024 Annual Report,the Company wishes to provide to the shareholders and potential investors of the Company with the following additional information in

5、 relation to the 2013 Share Option Scheme pursuant to the Rule 17.07 and 17.09 of the Listing Rules.(a)Total number of shares available for issueThe total number of shares available for issue under the 2013 Scheme(excluding treasury shares)is 599,889,841 shares representing approximately 9.9%of the

6、issued share capital of the Company as at 31 December 2024.However,since the 2013 Scheme has been expired on 23 May 2023,there is no option could be granted under the 2013 Scheme since then.2(b)Exercise periodAn option may be exercised in accordance with the terms of the 2013 Scheme at any time duri

7、ng a period to be determined and notified by the Directors to each grantee,which period may commence on the day on which the offer is made but shall end in any event not later than 10 years from the offer date subject to the provisions for early termination thereof.(c)Vesting periodUnless the Direct

8、ors otherwise determined and stated in the offer to the participant,there is no minimum period for which an option granted under the 2013 Scheme must be held before it can be exercised.(d)The remaining life of the 2013 SchemeSubject to any early termination determined by the Board in accordance with

9、 the terms of the 2013 Scheme,the 2013 Scheme is valid and effective for a term of 10 years commencing on its adoption date(i.e.24 May 2013).Accordingly,the 2013 Scheme has been expired on 23 May 2023,however,the provisions of the 2013 Scheme shall remain in full force and holders of all options gra

10、nted under it prior to such termination shall be entitled to exercise the outstanding options pursuant to the terms of it until expiry of the said options.3(e)Movements in the Companys share options outstanding during the yearThe following table discloses movements in the Companys share options outs

11、tanding during the year:Name or category of participantDate of grant of share optionsNumber of share optionsVesting period of share optionsExercise period of share optionsExercise price of share options At 1 January 2024Granted during the yearExercised during the yearLapsed during the yearAt 31 Dece

12、mber 2024HK$per shareDirectors,chief executive and a substantial shareholder and their associatesMr.Zhu Shi Xing2 April 201520,000,00020,000,000(i)2 April 2016 to 1 April 20250.6128 January 201610,000,00010,000,000(ii)28 January 2016 to 27 January 20170.53 30,000,00030,000,000Mr.Liu Xue Heng2 April

13、201520,000,00020,000,000(i)2 April 2016 to 1 April 20250.6128 January 201610,000,00010,000,000(ii)28 January 2016 to 27 January 20170.53 30,000,00030,000,000Mr.Gu Shan Chao2 April 201520,000,00020,000,000(i)2 April 2016 to 1 April 20250.6128 January 201610,000,00010,000,000(ii)28 January 2016 to 27

14、January 20170.53 30,000,00030,000,000Mr.Wang Zheng Chun2 April 201520,000,00020,000,000(i)2 April 2016 to 1 April 20250.6128 January 201610,000,00010,000,000(ii)28 January 2016 to 27 January 20170.53 30,000,00030,000,000Mr.Siu Kin Wai2 April 201510,000,00010,000,000(i)2 April 2016 to 1 April 20250.6

15、1Mr.Hu Shiang Chi2 April 20155,000,000(5,000,000)(i)2 April 2016 to 1 April 20250.6128 January 201610,000,000(10,000,000)(ii)28 January 2016 to 27 January 20170.53 15,000,000(15,000,000)4 Name or category of participantDate of grant of share optionsNumber of share optionsVesting period of share opti

16、onsExercise period of share optionsExercise price of share options At 1 January 2024Granted during the yearExercised during the yearLapsed during the yearAt 31 December 2024HK$per shareMr.Robert Winslow Koepp2 April 20155,000,000(5,000,000)(i)2 April 2016 to 1 April 20250.6128 January 20162,000,000(

17、2,000,000)(ii)28 January 2016 to 27 January 20170.53 7,000,000(7,000,000)Mr.Wu Yong Xin 2 April 20152,000,0002,000,000(i)2 April 2016 to 1 April 20250.6128 January 20162,000,0002,000,000(ii)28 January 2016 to 27 January 20170.53 4,000,0004,000,000Mr.Tse Man Kit,Keith2 April 20152,000,0002,000,000(i)

18、2 April 2016 to 1 April 20250.6128 January 20162,000,0002,000,000(ii)28 January 2016 to 27 January 20170.53 4,000,0004,000,000Mr.Zhang Yun Zhou28 January 20162,000,0002,000,000(ii)28 January 2016 to 27 January 20170.53 Sub-total162,000,000(22,000,000)140,000,000 Other employeesIn aggregate2 April 20

19、1552,500,00052,500,000(i)2 April 2016 to 1 April 20250.6128 January 201643,500,00043,500,000(ii)28 January 2016 to 27 January 20170.53 Sub-total96,000,00096,000,000 Total258,000,000(22,000,000)236,000,000 5 Notes:(i)First 30%of the options granted were vested from 2 April 2016,second 30%of the optio

20、ns granted were vested from 2 April 2017 and remaining 40%of the options granted were vested from 2 April 2018.Upon the lapse of the vesting period,the share options are exercisable until 1 April 2025.(ii)First 30%of the options granted were vested from 28 January 2017,second 30%of the options grant

21、ed were vested from 28 January 2018 and remaining 40%of the options granted were vested from 28 January 2019.Upon the lapse of the vesting period,the share options are exercisable until 27 January 2026.The above additional information does not affect other information contained in the 2024 Annual Re

22、port.Save as disclosed above,all other information in the 2024 Annual Report remains unchanged.By Order of the Board ofBeijing Health(Holdings)LimitedZhu Shi XingChairmanHong Kong,19 May 2025As at the date of this announcement,the Board comprises five Executive Directors,namely Mr.Zhu Shi Xing,Mr.Liu Xue Heng,Mr.Gu Shan Chao,Mr.Siu Kin Wai and Mr.Wang Zheng Chun and four Independent Non-Executive Directors,namely Mr.Tse Man Kit,Keith,Mr.Wu Yong Xin,Mr.Zhang Yun Zhou and Ms.Yang Xiao Yan.